vTv Therapeutics Inc. (VTVT) stock
VTVTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/3064% below fair value
$16.23−1.06 (-6.13%)
Close on Nov 18, 2026Market cap $64.17MP/E –Yield –
vTv Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
vTv Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$9.25M. For fiscal 2025 it was -$32.81M. The highest annual figure on record is -$11.85M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$32.81M | – |
| FY2024 | Dec 31, 2024 | -$24.18M | – |
| FY2023 | Dec 31, 2023 | -$25.50M | – |
| FY2022 | Dec 31, 2022 | -$22.54M | – |
| FY2021 | Dec 31, 2021 | -$21.66M | – |
| FY2020 | Dec 31, 2020 | -$11.85M | – |
| FY2019 | Dec 31, 2019 | -$20.89M | – |
| FY2018 | Dec 31, 2018 | -$19.82M | – |
| FY2017 | Dec 31, 2017 | -$50.68M | – |
| FY2016 | Dec 31, 2016 | -$55.02M | – |
| FY2015 | Dec 31, 2015 | -$38.14M | – |
| FY2014 | Dec 31, 2014 | -$28.90M | – |
| FY2013 | Dec 31, 2013 | -$35.83M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$13.93M | – |
| Q1 FY2026 | Mar 31, 2026 | $23.26M | – |
| Q4 FY2025 | Dec 31, 2025 | -$7.89M | – |
| Q3 FY2025 | Sep 30, 2025 | -$10.70M | – |
| Q2 FY2025 | Jun 30, 2025 | -$7.72M | – |
| Q1 FY2025 | Mar 31, 2025 | -$6.50M | – |
| Q4 FY2024 | Dec 31, 2024 | -$4.89M | – |
| Q3 FY2024 | Sep 30, 2024 | -$6.51M | – |
| Q2 FY2024 | Jun 30, 2024 | -$7.16M | – |
| Q1 FY2024 | Mar 31, 2024 | -$5.63M | – |
| Q4 FY2023 | Dec 31, 2023 | -$4.71M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.37M | – |
| Q2 FY2023 | Jun 30, 2023 | -$8.00M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.43M | – |
| Q4 FY2022 | Dec 31, 2022 | -$6.34M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.69M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.03M | – |
| Q1 FY2022 | Mar 31, 2022 | -$6.48M | – |
| Q4 FY2021 | Dec 31, 2021 | -$11.11M | -707.0% |
| Q3 FY2021 | Sep 30, 2021 | -$1.60M | – |
| Q2 FY2021 | Jun 30, 2021 | -$4.67M | – |
| Q1 FY2021 | Mar 31, 2021 | -$4.28M | – |
| Q4 FY2020 | Dec 31, 2020 | $1.83M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.83M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.20M | – |
| Q1 FY2020 | Mar 31, 2020 | -$6.65M | – |
| Q4 FY2019 | Dec 31, 2019 | -$6.39M | – |
| Q3 FY2019 | Sep 30, 2019 | -$5.43M | – |
| Q2 FY2019 | Jun 30, 2019 | -$4.79M | – |
| Q1 FY2019 | Mar 31, 2019 | -$4.29M | – |
| Q4 FY2018 | Dec 31, 2018 | -$351.00K | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.48M | – |
| Q2 FY2018 | Jun 30, 2018 | -$8.86M | – |
| Q1 FY2018 | Mar 31, 2018 | -$9.13M | – |
| Q4 FY2017 | Dec 31, 2017 | -$12.77M | – |
| Q3 FY2017 | Sep 30, 2017 | -$11.54M | – |
| Q2 FY2017 | Jun 30, 2017 | -$12.62M | – |
| Q1 FY2017 | Mar 31, 2017 | -$13.75M | – |
| Q4 FY2016 | Dec 31, 2016 | -$13.31M | – |
| Q3 FY2016 | Sep 30, 2016 | -$13.53M | – |
See a number that looks wrong?